SPAC JATT II Acquisition files for a $60 million IPO, targeting biotech and life sciences
IPO Overview
JATT II Acquisition, a blank check company targeting biotechs and life sciences businesses, filed on Friday with the SEC to raise up to $60 million in an initial public offering.
The company plans to raise $60 million by offering 6 million shares at $10. The company is not offering units with warrants or rights attached.
JATT II Acquisition is led by CEO and Chairman Someit Sidhu, who has founded and led several healthcare companies, most recently Khanda Therapeutics, where he serves as CEO. The SPAC plans to target healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences.
Sidhu’s previous SPAC, JATT Acquisition, completed its combination with hair loss biotech Zura Bio （ZURA; -31% from $10 offer price） in 2023.
The Westfield, NJ-based company was founded in 2026. It plans to list on the Nasdaq but has not selected a symbol yet （RC ticker: JATT.RC）。 Guggenheim Securities is the sole bookrunner on the deal.
About the Company
We are a blank check company. While we may pursue an initial business combination in any business or industry, we intend to focus our search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, we intend to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of our management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. We expect to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. Our management team is led by Dr. Someit Sidhu, our Chairman and Chief Executive Officer, and Mr. Nicholas Fernandez, our Chief Financial Officer, each of whom has significant experience building, operating and investing in the life sciences and medical technology sectors globally.
